EXPAND is a prospective, blinded, multi-site clinical trial with diagnostic outcomes on all subjects AUSTIN, Texas / Oct 01, 2025 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing and precision medicine, today announced a milestone in the EXPAND trial with the enrollment of over 1,600 patients. Initiated in 2023, EXPAND is designed to be the defining prospective clinical trial in... Read More

Largest ever ctDNA study in testicular cancer shows Signatera significantly outperformed standard of care tumor markers AUSTIN, Texas / Sep 30, 2025 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication of a peer-reviewed manuscript in the Journal of Clinical Oncology - Precision Oncology (JCO PO) . The paper features results from a... Read More

Signatera outperformed all available risk stratification tools in postoperative and post-definitive therapy settings AUSTIN, Texas / Sep 29, 2025 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication of a new study in the Journal of Clinical Oncology Precision Oncology (JCO PO), validating Signatera for recurrence monitoring and treatment... Read More

AUSTIN, Texas / Aug 29, 2025 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today provided an update regarding its intellectual property litigation with NeoGenomics, Inc. The U.S. District Court for the Middle District of North Carolina issued a ruling invalidating certain claims in two patents that Natera asserted against NeoGenomics’ v1.1 RaDaR test. Natera is... Read More

Randomized study aims to reduce treatment burden for patients and utilizes Signatera to monitor for disease recurrence AUSTIN, Texas / Aug 28, 2025 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the activation of the NRG Oncology trial, ARCHER (NRG-GU015), a randomized, phase III study in muscle-invasive bladder cancer (MIBC). The study is evaluating... Read More

AUSTIN, Texas / Aug 25, 2025 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that it will present new data at the 2025 International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer, taking place September 6 - 9 in Barcelona, Spain. The presentations underscore the strong clinical utility of Signatera in lung cancer. An... Read More

AUSTIN, Texas / Aug 22, 2025 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing and precision medicine, today announced the publication of more than 300 peer-reviewed papers featuring its technology and reinforcing its long-standing commitment to robust clinical evidence and scientific research. These publications span high-impact journals – such as Nature , Nature Medicine , the American... Read More

Proprietary platform is built on one of the largest multimodal oncology datasets, including 250,000+ tumor exomes, 1 million+ plasma timepoints, and enriched clinical and imaging records AUSTIN, Texas / Aug 22, 2025 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the launch of its proprietary AI foundation model platform. These models and applications,... Read More

Topline results from the trial show that Signatera-positive patients treated with atezolizumab (Tecentriq®) had statistically significant and clinically meaningful improvements in disease-free survival and overall survival IMvigor011 is the first prospective phase III study in muscle-invasive bladder cancer to read out that uses a personalized, ctDNA MRD*-guided approach AUSTIN, Texas / Aug 18, 2025 / Business Wire / Natera,... Read More

AUSTIN, Texas / Aug 07, 2025 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today reported its financial results for the second quarter ended June 30, 2025. Recent Financial Highlights Generated total revenues of $546.6 million in the second quarter of 2025, compared to $413.4 million in the second quarter of 2024, an increase of 32.2%. Product revenues grew 32.3% over... Read More

Launch supported by strong assay performance in first milestone readout of the landmark EXPAND clinical trial AUSTIN, Texas / Aug 07, 2025 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing and precision medicine, today announced the launch of Fetal Focus, a noninvasive prenatal test (NIPT) for inherited conditions. When a pregnant patient is identified as a carrier of a recessive... Read More

High-impact datasets across heart, kidney and lung at WTC follows two major publications in the American Journal of Transplantation in the last three months AUSTIN, Texas / Aug 01, 2025 / Business Wire / Natera, Inc. ( NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that it will present several new datasets at the 2025 World Transplant Congress (WTC), taking place August 2 - 6 in San... Read More

AUSTIN, Texas / Jul 31, 2025 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that it will release results for its second quarter ended June 30, 2025, after the market closes on August 7, 2025. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET). Earnings Conference Call Information Event: Natera’s Second... Read More

Study utilizes Signatera to identify HR+, HER2-negative breast cancer patients for de-escalation of neoadjuvant chemotherapy AUSTIN, Texas / Jul 29, 2025 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the launch of the TEODOR trial (Neoadjuvant T r E atment O ptimization driven by ct D NA and end O crine R esponsiveness). TEODOR is a Phase II,... Read More

First prospective, multi-center trial to examine how dd-cfDNA can be used in post-rejection patient management AUSTIN, Texas / Jul 24, 2025 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing and precision medicine, today announced that the American Journal of Transplantation published findings from the PEDAL study. PEDAL is the first prospective multi-center trial evaluating longitudinal... Read More

AUSTIN, Texas / Jul 07, 2025 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced data from a colorectal cancer (CRC) study of its tissue-free Latitude™ MRD assay, which were presented at the 2025 European Society for Medical Oncology GI Congress (ESMO GI). The clinical performance of the assay was analyzed in a cohort of ~200 patients (>1,300 plasma samples)... Read More

AUSTIN, Texas / Jul 01, 2025 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, announced new data that will be presented at the 2025 European Society for Medical Oncology GI Congress (ESMO GI) in Barcelona, Spain. These presentations reinforce the strong clinical and economic utility of Signatera™ monitoring across colon and rectal cancers (CRC), as well as new clinical... Read More

Broad coverage, inclusive of all previously covered Signatera indications AUSTIN, Texas / Jun 04, 2025 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that its genome-based Signatera MRD assay is now covered by Medicare under LCD L38779. This coverage decision applies to Medicare beneficiaries with colorectal cancer, breast cancer, bladder cancer,... Read More

Overall pan-cancer sensitivity of 94% and specificity of 100%, with analytical detection down to 1 PPM AUSTIN, Texas / Jun 02, 2025 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, announced results from a large-scale pan-cancer study of its Signatera Genome assay, which was presented today, June 2nd, at the 2025 American Society of Clinical Oncology (ASCO) Annual... Read More

Studies include nearly 25,000 patients across multiple indications, showcasing the clinical impact of Signatera Breast: 8 accepted abstracts (4 oral presentations), including interim analysis from the randomized Signatera-guided interventional DARE trial; a large real-world study of metastatic treatment monitoring; and two readouts from the ISPY-2 trial Signatera Genome: Large-scale, pan-cancer performance of Signatera... Read More

AUSTIN, Texas / May 08, 2025 / Business Wire / Natera, Inc . (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today reported its financial results for the first quarter ended March 31, 2025. Recent Strategic and Financial Highlights Generated total revenues of $501.8 million in the first quarter of 2025, compared to $367.7 million in the first quarter of 2024, an increase of 36.5%. Product revenues... Read More

Demonstrates Signatera’s ability to predict long-term outcomes in early-stage, high-risk breast cancers Several datasets will be presented, highlighting Natera’s leadership in breast cancer MRD AUSTIN, Texas / May 08, 2025 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, will present multiple datasets in breast cancer together with its collaborators at the 2025 ESMO... Read More

Study published in American Journal of Transplantation highlights strong sensitivity and specificity, along with a >37% reduction in false positives when using Prospera Heart with DQS Adds to the growing body of evidence supporting DQS for dd-cfDNA analysis in solid organ transplant AUSTIN, Texas / May 07, 2025 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today... Read More

Stanford-led study included over 2,100 Signatera samples from over 200 sarcoma patients, with overall sensitivity of 89% and specificity of 100% Leiomyosarcoma, the most common subtype in the cohort, demonstrated sensitivity of 93% and specificity of 100% AUSTIN, Texas / May 05, 2025 / Business Wire / Natera, Inc . (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the results of a study... Read More

AUSTIN, Texas / May 01, 2025 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that it will release results for its first quarter ended March 31, 2025, after the market closes on May 8, 2025. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET). Earnings Conference Call Information Event: Natera’s First Quarter 2025... Read More

Prospera Heart with donor quantity score (DQS) demonstrates significant correlation with clinical outcomes AUSTIN, Texas / Apr 29, 2025 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, announced the results of its DEFINE-HT clinical trial in heart transplantation, which were shared today, April 29, 2025, in an oral presentation at the International Society for Heart and... Read More

Extensive pan-cancer validation data from over 3,000 plasma samples to be presented at ASCO AUSTIN, Texas / Apr 24, 2025 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that its ultra-sensitive Signatera Genome assay is now broadly available to physicians in the United States. This launch is supported by a large genome-based molecular residual disease (MRD)... Read More

Data spans immunotherapy (IO) response prediction and genomic landscaping in colorectal cancer (CRC), breast cancer, and gynecological cancers AUSTIN, Texas / Apr 22, 2025 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that data from 8 studies will be shared at the American Association of Cancer Research (AACR) Annual Meeting that will take place April 25... Read More

First-of-its-kind prospective trial evaluates the association between dd-cfDNA and clinical outcomes in heart transplantation using Prospera™ Heart with Donor Quantity Score (DQS) AUSTIN, Texas / Mar 25, 2025 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, announced that it will share results from the DEFINE-HT study in a late-breaking oral presentation at the... Read More

HEROES is Natera’s first clinical trial using Signatera™ to guide de-escalation of therapy in patients with metastatic HER2+ breast cancer Approximately 170 patients are expected to enroll in up to 35 sites in France AUSTIN, Texas / Mar 10, 2025 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced the enrollment of the first patients in the HEROES clinical... Read More

AUSTIN, Texas / Mar 04, 2025 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that the U.S. Patent and Trademark Office has issued Natera a new patent related to testing of single nucleotide variants in circulating-tumor DNA (ctDNA). This builds on Natera’s extensive intellectual property estate, including a strong portfolio of molecular residual disease... Read More

AUSTIN, Texas / Feb 27, 2025 / Business Wire / Natera, Inc . (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today reported its financial results for the fourth quarter and full year ended December 31, 2024. Recent Financial Highlights Generated total revenues of $476.1 million in the fourth quarter of 2024, compared to $311.1 million in the fourth quarter of 2023, an increase of 53.0%. Product revenues... Read More

AUSTIN, Texas / Feb 25, 2025 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that its Signatera test has met coverage requirements from the Centers for Medicare & Medicaid Services’ (CMS) Molecular Diagnostics Services Program (MolDX) for patients with non-small cell lung cancer (NSCLC). This coverage applies to patients with stage I-III NSCLC with... Read More

AUSTIN, Texas / Feb 18, 2025 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that it will release results for its fourth quarter and year ended Dec. 31, 2024, after the market closes on Feb. 27, 2025. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET). Earnings Conference Call Information Event: Natera’s Fourth... Read More

National Comprehensive Cancer Network® (NCCN®) Guidelines for colon and rectal cancer were updated to include ctDNA as a prognostic marker and high risk factor for recurrence NCCN guideline for merkel cell carcinoma cites Signatera TM data and now includes positive recommendation for ctDNA monitoring in surveillance AUSTIN, Texas / Feb 10, 2025 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA... Read More

Coverage from one of the largest payors in the country expands access to fetal RhD testing for pregnant patients nationwide AUSTIN, Texas / Feb 03, 2025 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced a new policy for commercial coverage of its cfDNA Fetal RhD noninvasive prenatal test (Fetal RhD NIPT) from one of the largest payors in the United... Read More

Readout of ~1K patients at ASCO GI 2025 demonstrates that Signatera™ positive patients treated with both chemotherapy and celecoxib had a 40% improvement in overall survival versus chemotherapy alone Additional ASCO GI poster highlights data from the ALTAIR clinical trial, showing significant clinical benefit in patients with stage IV colorectal cancer who were treated with Trifluridine/Tipiracil (FTD/TPI) AUSTIN, Texas, /... Read More

First set of abstracts released include Signatera™ data from BESPOKE CRC, the largest prospective, observational, multicenter MRD study in the U.S. to date, along with the first read-outs in early cancer detection and tissue-free MRD Additional Signatera data will be shared at ASCO GI on Jan. 25, 2025, including a late-breaking oral presentation on the CALGB (Alliance) / SWOG 80702 study AUSTIN, Texas / Jan 21, 2025 /... Read More

AUSTIN, Texas / Jan 17, 2025 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that its CEO, Steve Chapman, has been selected as one of the top healthcare technology CEOs for 2024, as determined by Healthcare Technology Report . Chapman was also named... Read More

Company to provide comprehensive update in a presentation delivered today at the 43rd Annual J.P. Morgan Healthcare Conference Presentation outlines strength of existing oncology portfolio, along with pipeline of new products and data readouts AUSTIN, Texas / Jan 15, 2025 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, will provide an update to the investment community, today, at the... Read More

2024 revenues are expected to increase by approximately 56% compared to 2023, which is approximately $53 million above top end of financial outlook Additional business updates to be presented by Natera at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025 AUSTIN, Texas / Jan 12, 2025 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today released... Read More

Amended complaint asserts infringement of U.S. Patent Nos. ‘596 and ‘454 by the modified version of NeoGenomics’ RaDaR assay AUSTIN, Texas / Dec 17, 2024 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced an expansion of its patent infringement lawsuit against NeoGenomics, Inc. related to its RaDaR® tests. On December 10, 2024, the District Court for... Read More

SAGITTARIUS is Natera's first interventional trial using Signatera TM to select patients for targeted therapy in early-stage colon cancer Approximately 700-900 patients expected to be enrolled across more than 20 sites AUSTIN, Texas / Dec 12, 2024 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced the enrollment of the first patients in the SAGITTARIUS... Read More

Cross-ancestry polygenic risk score now offered with the Empower™ hereditary cancer test AUSTIN, Texas / Dec 09, 2024 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, and MyOme, a leading clinical whole genome analysis and polygenic risk modeling company, today announced the launch of an integrated polygenic risk score (iPRS) for personalized breast cancer risk assessment.... Read More

Test demonstrated high performance metrics in largest study of its kind in the US with sensitivity of 100% and specificity of 99.3% AUSTIN, Texas / Dec 02, 2024 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that Obstetrics & Gynecology (also known as The Green Journal ) published the Company’s clinical validation study on its cell-free DNA (cfDNA) Fetal... Read More

AUSTIN, Texas / Nov 27, 2024 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that its Prospera Lung test has met coverage requirements from the Centers for Medicare & Medicaid Services’ (CMS) Molecular Diagnostics Services (MolDX) Program for single lung transplant (SLT) recipients. This coverage applies to SLT patients in the surveillance setting. SLT... Read More

AUSTIN, Texas / Nov 25, 2024 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that it will present new Signatera TM data at the San Antonio Breast Cancer Symposium (SABCS), taking place Dec. 10-13 in San Antonio, TX. Natera and its collaborators will present a total of six abstracts. “We are proud to share this new data on Signatera at SABCS that underscores... Read More

AUSTIN, Texas / Nov 25, 2024 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today issued the following statement: In 2021, Natera and Guardant Health filed false advertising cases against each other concerning statements both companies made more than three years ago about Guardant’s Reveal test. Today, a jury issued a decision in Guardant’s favor. We disagree with this... Read More

AUSTIN, Texas / Nov 25, 2024 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that its co-founder and executive chairman, Matthew Rabinowitz, PhD, has been named R&D Leader of the Year by R&D World . Established in 1963, the R&D 100 Awards program identifies and celebrates the top 100 revolutionary technologies of the past year. R&D World also has five... Read More

Underscores the Company’s commitment to generating robust scientific evidence on its leading MRD technology AUSTIN, Texas / Nov 21, 2024 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that it has surpassed a key milestone with over 100 peer-reviewed publications on its personalized and tumor-informed molecular residual disease (MRD) test, Signatera.... Read More

AUSTIN, Texas / Nov 12, 2024 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today reported its financial results for the third quarter ended September 30, 2024. Recent Strategic and Financial Highlights Generated total revenues of $439.8 million in the third quarter of 2024, compared to $268.3 million in the third quarter of 2023, a record increase of 63.9%. Product... Read More

First-of-its-kind study of >1K patients evaluating the impact of adjuvant treatment escalation in patients tested with Signatera™; results to be presented at ASCO GI in Jan. 2025 AUSTIN, Texas / Nov 12, 2024 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced the completion of a study using Signatera from the CALGB (Alliance)/SWOG 80702 randomized, phase III... Read More

AUSTIN, Texas / Nov 08, 2024 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that members of its leadership team will present at the following investor conferences in November and December. The UBS Global Healthcare Conference on Thursday, Nov. 14 at 11:00 am ET | 8:00 am PT in Rancho Palos Verdes, CA. The Wolfe Research Healthcare Conference on Tuesday,... Read More

AUSTIN, Texas / Nov 01, 2024 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that it will release results for its third quarter ended Sept. 30, 2024, after the market closes on Nov. 12, 2024. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET). Earnings Conference Call Information: Event: Natera’s Third Quarter... Read More

AUSTIN, Texas / Oct 22, 2024 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced that the company will present new data on its 385-gene kidney genetic test, Renasight™ , at the annual meeting of the American Society of Nephrology (ASN) Kidney Week 2024. The meeting will take place in San Diego from Oct. 23-27. Natera and its collaborators will present 7... Read More

AUSTIN, Texas / Sep 23, 2024 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today issued the following statement regarding its ongoing patent infringement litigation with NeoGenomics in response to inquiries: On Sept. 23, 2024, the District Court for the Middle District of North Carolina entered a permanent injunction against NeoGenomics’ accused RaDaR assay,... Read More

Signatera now has >85 peer-reviewed publications with clinical validation across multiple cancer types and indications AUSTIN, Texas / Sep 16, 2024 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced the simultaneous publication of three peer-reviewed papers, crossing a milestone of more than 85 peer-reviewed publications on Signatera. This includes:... Read More

Shows nearly 10x advantage in overall survival at 36 months based on ctDNA status and affirms Signatera’s ability to predict chemotherapy benefit Shows a 50% reduction in risk of death for Signatera-positive patients when treated with ACT AUSTIN, Texas / Sep 14, 2024 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, announced that new data from the GALAXY arm of the ongoing... Read More

Presentations include abstracts from the GALAXY arm of the CIRCULATE-Japan trial, along with new data in Breast Cancer and Squamous Cell Carcinoma of the Head and Neck AUSTIN, Texas / Sep 08, 2024 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced it will present new data on its personalized and tumor-informed molecular residual disease (MRD) test, Signatera,... Read More

AUSTIN, Texas / Aug 28, 2024 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that members of its leadership team will present at the Morgan Stanley 22nd Annual Global Healthcare Conference on Wednesday, Sept. 4 at 2:35 pm ET | 11:35 am PT in New York City. A live webcast and audio archive of the event may be accessed through the investor relations section... Read More

AUSTIN, Texas / Aug 08, 2024 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today reported its financial results for the second quarter ended June 30, 2024. Recent Strategic and Financial Highlights Generated total revenues of $413.4 million in the second quarter of 2024, compared to $261.4 million in the second quarter of 2023, an increase of 58.1%. Product revenues grew... Read More

AUSTIN, Texas / Aug 06, 2024 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that members of its leadership team will present at the Canaccord Genuity 44th Annual Growth Conference on Wednesday, Aug. 14 at 12:30 pm ET | 9:30 am PT in Boston, MA. A live webcast and audio archive of the event may be accessed through the investor relations section of the Natera website at... Read More

AUSTIN, Texas / Jul 30, 2024 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will release results for its second quarter ended June 30, 2024, after the market close on Aug. 8, 2024. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET). Earnings Conference Call Information: Event: Natera’s Second Quarter 2024 Financial... Read More

Study reports high accuracy of Signatera for surveillance of MCC patients, suggests potential to reduce frequency of surveillance imaging AUSTIN, Texas / Jul 26, 2024 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a new study published in the Journal of Clinical Oncology highlighting the utility of its personalized and tumor-informed molecular residual disease (MRD)... Read More

AUSTIN, Texas / Jul 03, 2024 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced that its latest research and data on prenatal and reproductive genetics will be presented at the 28th International Conference on Prenatal Diagnosis and Therapy. Hosted by the International Society of Prenatal Diagnosis (ISPD), the conference will take place July 7-10,... Read More

First-of-its-kind study in gastroesophageal adenocarcinoma using Signatera to guide treatment and assess the efficacy of a novel HER2-directed adjuvant treatment AUSTIN, Texas / Jun 27, 2024 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced a new gastroesophageal cancer trial, DECIPHER, that will utilize the company’s personalized and tumor-informed... Read More

Donor Quantity Score (DQS) technique is unique to Natera, improving detection of both acute cellular rejection and antibody-mediated rejection AUSTIN, Texas / Jun 17, 2024 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced the launch of Prospera Heart™ with Donor Quantity Score (DQS), further enhancing Prospera’s ability to detect rejection in heart... Read More

AUSTIN, Texas / Jun 03, 2024 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that it will present at the Goldman Sachs 45th Annual Global Healthcare Conference on Monday, June 10, 2024 at 7:40 a.m. PT (10:40 a.m. ET). A live webcast may be accessed through the investor relations section of the Natera website at investor.natera.com . A replay of the event... Read More

Includes new results from the ProActive study, reinforcing the utility of the Prospera™ Kidney test for ongoing surveillance of transplant rejection AUSTIN, Texas / May 30, 2024 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced that the company will present new data on its Prospera donor-derived cfDNA (dd-cfDNA) test at the American Transplant... Read More

AUSTIN, Texas / May 23, 2024 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that members of Natera’s management will present at the 2024 Leerink Partners Healthcare Crossroads Conference on Thursday, May 30, 2024 at 8:40 a.m. PT (11:40 a.m. ET). A live webcast may be accessed through the investor relations section of the Natera website at... Read More

AUSTIN, Texas / May 23, 2024 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that the company, along with its collaborators, will present new data at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 31 – June 4, 2024. The presentations feature data across a variety of indications, including breast cancer, colorectal... Read More

AUSTIN, Texas / May 09, 2024 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today reported its financial results for the first quarter ended March 31, 2024. Recent Strategic and Financial Highlights Achieved positive cash flow of approximately $3.0 million 1 in the first quarter of 2024. Generated total revenues of $367.7 million in the first quarter of 2024, compared to... Read More

Expanded EBLIS study with up to 12 years of clinical follow-up across all subtypes of breast cancer AUSTIN, Texas / May 03, 2024 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced a new publication in JCO Precision Oncology reporting on the ability of its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, to detect recurrence... Read More

AUSTIN, Texas / May 01, 2024 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that it will release results for its first quarter ended March 31, 2024, after the market close on May 9, 2024. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET). Earnings Conference Call Information: Event: Natera’s First Quarter 2024... Read More

Backed by large clinical validation study with over 650 RhD-negative patients with confirmed outcomes, resulting in 100% sensitivity and >99% specificity AUSTIN, Texas / May 01, 2024 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced the launch of a new cfDNA-based fetal RhD test. This comes at a critical time for the healthcare industry, helping... Read More

Demonstrates commitment to generating real-world clinical evidence to change disease management and improve patient outcomes AUSTIN, Texas / Apr 22, 2024 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced that it has passed a significant milestone with the publication of more than 200 peer-reviewed papers highlighting Natera’s technology in the... Read More

ProActive study shows Natera’s Prospera Kidney™ test detects rejection five months before biopsy AUSTIN, Texas / Apr 11, 2024 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced a new publication from the ProActive study in Transplantation supporting the use of the Prospera Kidney donor-derived cfDNA (dd-cfDNA) test as a leading indicator of kidney transplant... Read More

Prospective, multi-center Trifecta-Heart and DTRT-2 studies demonstrate excellent performance of the Prospera Heart test for detecting rejection in adults and pediatrics AUSTIN, Texas / Apr 08, 2024 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced the publication of two major studies, DTRT-2 and Trifecta-Heart, showcasing the ability of the Prospera Heart... Read More

Data demonstrates that MIBC patients who remain Signatera MRD-negative after surgery may be spared from adjuvant treatment, with 100% overall survival at 12 months AUSTIN, Texas / Apr 05, 2024 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced an analysis from the IMvigor011 study that was presented at the European Association of Urology (EAU) Congress 2024 in Paris,... Read More

First of its kind study in muscle-invasive urothelial cancer, with both escalation and de-escalation arms Approximately 1,000 patients will be enrolled at more than 300 sites AUSTIN, Texas / Apr 01, 2024 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, and the Alliance for Clinical Trials in Oncology, which is part of the National Clinical Trials Network (NCTN) funded by the National... Read More

AUSTIN, Texas / Mar 18, 2024 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a collaboration with the Fédération Francophone de Cancérologie Digestive and CHU Dijon Bourgogne on the CIRCULATE-PRODIGE-70 study, a randomized, multicenter, prospective phase III clinical trial in France investigating molecular residual disease (MRD)-guided adjuvant treatment in stage II... Read More

Supports broader adoption of Natera’s Renasight TM test AUSTIN, Texas / Mar 14, 2024 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, commented today on the 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease , which was recently published by the Kidney Disease Improving Global Outcomes (KDIGO) organization, a leading medical society in... Read More

AUSTIN, Texas / Mar 12, 2024 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced new data being presented on its personalized and tumor-informed molecular residual disease (MRD) test, Signatera™, and hereditary cancer test, Empower™, at the 2024 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer taking place March 16-18, 2024. A total of seven abstracts... Read More

AUSTIN, Texas / Mar 07, 2024 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced that it has received commercial insurance coverage for its Prospera Heart and Prospera Kidney tests from one of the largest Blue Cross Blue Shield (BCBS) plans in the U.S. Prospera is a non-invasive blood test that analyzes donor-derived cfDNA (dd-cfDNA) to evaluate the risk of organ... Read More

AUSTIN, Texas / Feb 29, 2024 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will participate in the following investor conferences in March. Raymond James 45th Annual Institutional Investors Conference Tuesday, March 5 at 2:15 pm ET | 11:15 am PT in Orlando, FL TD Cowen 44th Annual Health Care Conference Wednesday, March 6 at 9:50 am ET | 6:50 am PT in Boston,... Read More

AUSTIN, Texas / Feb 28, 2024 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today reported its financial results for the fourth quarter and year ended December 31, 2023. Recent Strategic and Financial Highlights Generated total revenues of $311.1 million in the fourth quarter of 2023, compared to $217.3 million in the fourth quarter of 2022, an increase of 43.2%. Product revenues... Read More

AUSTIN, Texas / Feb 27, 2024 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the next phase of proceedings in its patent infringement litigation against CareDx. The U.S. District Court for the District of Delaware will now determine if CareDx owes a royalty for future infringement related to ongoing and future AlloSure testing occurring after August 2023. This follows... Read More

AUSTIN, Texas / Feb 26, 2024 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, has met coverage requirements from the Centers for Medicare & Medicaid Services’ (CMS) Molecular Diagnostics Services Program (MolDX) in two new indications: ovarian cancer in the adjuvant and... Read More

AUSTIN, Texas / Feb 20, 2024 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will release results for its fourth quarter and year ended December 31, 2023, after the market close on Feb. 28, 2024. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET). Earnings Conference Call Information: Event: Natera’s Fourth Quarter... Read More

Study shows ctDNA positivity is the most prognostic factor, demonstrating the potential for Signatera to redefine adjuvant treatment pathways in endometrial cancer AUSTIN, Texas / Feb 05, 2024 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a new study published in Gynecologic Oncology validating its personalized and tumor-informed molecular residual disease (MRD)... Read More

Clinical management was altered in 100% of patients with a Signatera positive result AUSTIN, Texas / Jan 30, 2024 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a new study published in The Journal of Thoracic and Cardiovascular Surgery demonstrating the ability of Natera’s personalized and tumor-informed molecular residual disease (MRD) test, Signatera, to risk... Read More

Liability for future sales to be determined AUSTIN, Texas / Jan 29, 2024 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that a jury in the U.S. District Court for the District of Delaware has reached a unanimous verdict in favor of Natera in its patent infringement case against CareDx, Inc. The jury awarded Natera $83.7 million in lost profits and $12.6 million in... Read More

AMPLIFY-201, a phase I trial evaluating treatment response to the ELI-002 vaccine, is the first study to read out using ctDNA to enroll and monitor patients with solid tumors PANDA study shows ctDNA status in patients with gastric and gastroesophageal cancers is strongly associated with recurrence risk and pathologic response AUSTIN, Texas / Jan 25, 2024 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in... Read More

AUSTIN, Texas / Jan 22, 2024 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced that it has acquired from Invitae (NYSE: NVTA), a leading medical genetics company, certain assets relating to Invitae’s non-invasive prenatal screening and carrier screening business. Natera has made an upfront payment in the amount of $10 million to Invitae. In addition, the... Read More

Oral presentations include updated 24-month DFS analysis from GALAXY and first interim analysis from BESPOKE CRC AUSTIN, Texas / Jan 18, 2024 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that new data on its personalized and tumor-informed molecular residual disease (MRD) test, Signatera™, will be presented at the American Society of Clinical Oncology’s 2024... Read More

No willful infringement, damages significantly less than what Ravgen was seeking AUSTIN, Texas / Jan 16, 2024 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that a jury has reached a verdict in the United States District Court for the Western District of Texas regarding a patent infringement lawsuit brought by Ravgen, Inc. against Natera. Natera noted that the damages... Read More

2023 revenues are expected to be approximately $20 million above top end of guidance AUSTIN, Texas / Jan 09, 2024 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced preliminary revenue results for the fourth quarter and full year ended Dec. 31, 2023. The Company expects the following: Total revenues of approximately $300 million in the fourth quarter of 2023, an... Read More

AUSTIN, Texas / Dec 29, 2023 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will participate in the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Tuesday, Jan. 9, 2024 at 3:45 p.m. PT (6:45 p.m. ET). Members of Natera’s management will deliver a presentation and host a Q&A with the investment community at the conference. A live webcast... Read More

Order enjoins NeoGenomics from making, using, selling or promoting its RaDaR molecular residual disease (MRD) assay in the United States with limited exceptions AUSTIN, Texas / Dec 27, 2023 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that the federal District Court for the Middle District of North Carolina has issued a preliminary injunction, effective immediately,... Read More

Pan-cancer study showed MTM/mL dynamics were more predictive of therapy response than mVAF dynamics, with an observed hazard ratio nearly 2x higher AUSTIN, Texas / Dec 21, 2023 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a new study published in Molecular Oncology comparing the performance of mean tumor molecules per milliliter (MTM/mL) against mean variant allele... Read More

Natera successfully achieves key objective for trial set to begin on Jan. 22nd AUSTIN, Texas / Dec 11, 2023 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that the United States District Court for the District of Delaware has issued an order denying CareDx’s motion for summary judgment on two Natera patents in the infringement lawsuit filed by Natera against CareDx.... Read More

Includes new data from prospective clinical trials in HR+/HER2- breast cancer evaluating treatment on molecular recurrence (TOMR) and additional real-world data across all breast cancer subtypes AUSTIN, Texas / Dec 06, 2023 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced new data being presented on its personalized and tumor-informed molecular residual disease (MRD)... Read More

AUSTIN, Texas / Nov 14, 2023 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it has entered into an agreement with Merck, known as MSD outside the United States and Canada, under which Merck will utilize Natera’s real-world database (RWD) to advance oncology research. Natera’s oncology RWD contains de-identified clinical and genomic data from more than 100,000... Read More

AUSTIN, Texas / Nov 08, 2023 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today reported financial results for the third quarter ended September 30, 2023. Recent Strategic and Financial Highlights Generated total revenues of $268.3 million in the third quarter of 2023, compared to $210.6 million in the third quarter of 2022, an increase of approximately 27%. Product revenues grew... Read More

Study to evaluate effectiveness of switching treatment to elacestrant in early breast cancer based on the detection of molecular relapse with Signatera™ Approximately 1,900 early-stage breast cancer patients to be screened at 120+ sites in Europe AUSTIN, Texas / Nov 08, 2023 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced its personalized and tumor-informed molecular... Read More

AUSTIN, Texas / Nov 07, 2023 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will participate in the following investor conferences in November. • Stephens Annual Investment Conference Tuesday, Nov. 14 at 12:00 pm ET | 9:00 am PT in Nashville, TN • Piper Sandler 35th Annual Healthcare Conference Tuesday, Nov. 28 at 2:30 pm ET | 11:30 am PT in New York, NY A... Read More

Study found 1 in 5 patients was positive for a genetic cause of CKD, 1 in 2 positive patients received a new or reclassified diagnosis, and 1 in 3 positive patients had a change in treatment plan Diagnostic yield and utility exceed clinical precedents for implementation of routine genetic testing within an at-risk population 1-6 AUSTIN, Texas / Nov 02, 2023 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in... Read More

Builds on published evidence with twice as many patients and disease-free survival data extended to 24 months AUSTIN, Texas / Oct 22, 2023 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced updated data from the GALAXY arm of the CIRCULATE-Japan trial further showcasing the ability of the Signatera™ molecular residual disease (MRD) test to help identify patients with... Read More

AUSTIN, Texas / Oct 20, 2023 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will release results for its third quarter ended September 30, 2023, after the market close on Nov. 8, 2023. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET). Earnings Conference Call Information: Event: Natera’s Third Quarter 2023... Read More

AUSTIN, Texas / Oct 19, 2023 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it has been named by U.S. News & World Report as one of the best companies to work for in healthcare. Natera was ranked among 349 companies across 20 fields of work on factors contributing to job seekers’ decision-making when choosing a workplace that best meets their needs in their... Read More

Presentations include largest analysis from the GALAXY study in colorectal cancer with updated 24-month disease-free survival data, and expanded Signatera readout in rectal cancer AUSTIN, Texas / Oct 16, 2023 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced it will present new data on its personalized and tumor-informed molecular residual disease (MRD) test, Signatera,... Read More

Test performance showed 82% pre-treatment detection, with 100% longitudinal sensitivity and 100% longitudinal specificity to disease progression AUSTIN, Texas / Oct 04, 2023 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a new study published in Frontiers in Oncology demonstrating the ability of Natera’s personalized and tumor-informed molecular residual disease (MRD)... Read More

Final decision follows multiple previous court rulings in favor of Natera and upholds invalidation of CareDx patents AUSTIN, Texas / Oct 03, 2023 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced that the United States Supreme Court denied CareDx, Inc.’s (NASDAQ: CDNA) petition for certiorari concerning a patent infringement lawsuit brought by CareDx against... Read More

Lays groundwork for multiple submissions across cancer types, starting with CDx label in bladder cancer AUSTIN, Texas / Oct 02, 2023 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the submission of the first module of its premarket approval (PMA) application to the U.S. Food and Drug Administration (FDA) for Signatera, Natera’s personalized and tumor-informed... Read More

AUSTIN, Texas / Sep 18, 2023 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced three appointments within its senior leadership team, effective immediately. Solomon Moshkevich has been promoted to president of clinical diagnostics and will lead Natera’s team of general managers across oncology, women’s health, and organ health. In addition, Moshkevich will have... Read More

Prospective study to monitor 600 patients in real time, across all subtypes of breast cancer AUSTIN, Texas / Sep 14, 2023 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a new study as part of the I-SPY 2 trial, sponsored and operated by Quantum Leap Healthcare Collaborative, that will use Signatera, Natera’s personalized and tumor-informed molecular residual disease... Read More

AUSTIN, Texas / Sep 07, 2023 / Business Wire / Natera, Inc. (Nasdaq: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced the pricing of its underwritten public offering of 4,550,000 shares of its common stock at a price to the public of $55.00 per share. Closing of the offering is expected to occur on September 11, 2023, subject to customary closing conditions. In addition, Natera has granted the... Read More

AUSTIN, Texas / Sep 06, 2023 / Business Wire / Natera, Inc. (Nasdaq: NTRA) (“Natera”), a global leader in cell-free DNA (cfDNA) testing, today announced the launch of a proposed follow-on public offering of $250,000,000 of shares of its common stock. In addition, Natera expects to grant the underwriters a 30-day option to purchase up to an additional $37,500,000 of shares of its common stock at the public offering price less... Read More

AUSTIN, Texas / Sep 01, 2023 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that members of its management team will present at the following investor conferences: The Morgan Stanley 21st Annual Global Healthcare Conference on Monday, Sept. 11 at 4:55 p.m. ET in New York, NY The Baird 2023 Global Healthcare Conference on Tuesday, Sept. 12 at 4:20 p.m. ET in New York,... Read More

Represents third covered indication for Prospera AUSTIN, Texas / Aug 16, 2023 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced that it has received confirmation that its Prospera Lung donor-derived cfDNA (dd-cfDNA) transplant assessment test has met coverage requirements from the Centers for Medicare & Medicaid Services’ (CMS) Molecular Diagnostics Services... Read More

AUSTIN, Texas / Aug 03, 2023 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today reported financial results for the second quarter ended June 30, 2023. Recent Strategic and Financial Highlights Generated total revenues of $261.4 million in the second quarter of 2023, compared to $198.2 million in the second quarter of 2022, an increase of 31.9%. Product revenues grew 32.7% over the... Read More

AUSTIN, Texas / Aug 02, 2023 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that members of its leadership team will present at the Canaccord Genuity 43rd Annual Growth Conference on Wednesday, Aug. 9 at 4:30 pm ET | 1:30 pm PT in Boston, MA. A live webcast and audio archive of the event may be accessed through the investor relations section of the Natera website at... Read More

AUSTIN, Texas / Jul 31, 2023 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it has filed a lawsuit in the North Carolina Federal District Court against NeoGenomics Labs, Inc. ("NeoGenomics") for infringement of Natera's U.S. Patent Nos. 11,519,035 and 11,530,454 by NeoGenomics’ RaDaR molecular residual disease assay. This lawsuit builds on Natera's current patent... Read More

Study to evaluate clinical utility of ctDNA-guided treatment escalation for CRC patients; results expected to read out in mid-2024 AUSTIN, Texas / Jul 28, 2023 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the completion of enrollment to the randomized, double-blind phase III ALTAIR clinical trial (JapicCTI-205363/NCT04457297). ALTAIR is the circulating tumor DNA... Read More

AUSTIN, Texas / Jul 27, 2023 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will release results for its second quarter ended June 30, 2023, after the market close on Aug. 3, 2023. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET). Earnings Conference Call Information: Event: Natera’s Second Quarter 2023 Financial... Read More

AUSTIN, Texas / Jul 17, 2023 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that the United States District Court for the District of Delaware issued a decision in favor of Natera in the false advertising case brought by CareDx, Inc. In today’s decision, the Court reversed findings returned by a jury in March 2022 and ruled that CareDx is not entitled to any damages.... Read More

AUSTIN, Texas / Jun 06, 2023 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that members of its management team will present at the Goldman Sachs 44th Annual Global Healthcare Conference on Tuesday, June 13 at 5:40 pm ET | 2:40 pm PT in Dana Point, CA. A live webcast and audio archive of the event may be accessed through the investor relations section of the Natera... Read More

AUSTIN, Texas / Jun 04, 2023 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced new data on its Prospera test being presented at the American Transplant Congress (ATC) 2023 taking place June 3-7, 2023. The presentations include several interim analyses from ProActive, a prospective donor-derived cell-free DNA (dd-cfDNA) study evaluating Natera’s Prospera test for the... Read More

Highlights include oral presentations in Sarcoma and CRC; immunotherapy monitoring data from the Phase 3 EMPOWER-Lung 1 study; updates from the CIRCULATE-Japan study in CRC AUSTIN, Texas / May 30, 2023 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that new data on its personalized and tumor-informed molecular residual disease (MRD) test, Signatera™, will be presented... Read More

Natera has a broad, global IP portfolio of more than 360 issued or pending patents, with more than 180 in the field of oncology/MRD AUSTIN, Texas / May 15, 2023 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that a jury in the U.S. District Court for the District of Delaware has reached a unanimous verdict in favor of Natera in the patent infringement suit it filed... Read More

AUSTIN, Texas / May 09, 2023 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today reported financial results for the first quarter ended March 31, 2023. Recent Strategic and Financial Highlights Generated total revenues of $241.8 million in the first quarter of 2023, compared to $194.1 million in the first quarter of 2022, an increase of 24.5%. Product revenues grew 25.2% over the... Read More

Study with 283 patients, >1,000 plasma samples, and longest follow-up exceeding 5 years demonstrates how ctDNA monitoring can help inform treatment decisions in HR+/HER2- and TNBC patients AUSTIN, Texas / May 08, 2023 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the publication of a new paper 1 in Cancer Cell from the I-SPY2 trial, highlighting the prognostic and... Read More

AUSTIN, Texas / May 02, 2023 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will release results for its first quarter ended March 31, 2023, after the market close on May 9, 2023. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET). Earnings Conference Call Information: Event: Natera’s First Quarter 2023 Financial... Read More

Includes long-term follow-up data (>5 years) in patients with muscle-invasive bladder cancer and additional studies in colorectal, gastroesophageal and hepatocellular carcinoma AUSTIN, Texas / Apr 14, 2023 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced new data on its Signatera molecular residual disease (MRD) test being presented at the annual meeting of the American... Read More

Real-world findings from >550 plasma samples highlight prognostic and predictive value of Signatera for adjuvant decision-making and immunotherapy monitoring AUSTIN, Texas / Mar 22, 2023 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a new study published in Cancer showing the prognostic and predictive utility of Natera’s personalized and tumor-informed molecular... Read More

AUSTIN, Texas / Mar 02, 2023 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the Company’s first commercial coverage policies for its molecular residual disease test, Signatera, including its first pan-cancer coverage policy for adjuvant, recurrence monitoring, and treatment monitoring. Effective March 1, 2023, Blue Shield of California now provides commercial coverage... Read More

AUSTIN, Texas / Feb 24, 2023 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that members of its management team will present at the following investor conferences: Raymond James 44th Annual Institutional Investors Conference on Tuesday, March 7 at 2:50 p.m. ET in Orlando, FL Cowen 43rd Annual Health Care Conference on Wednesday, March 8 at 11:10 a.m. ET in Boston, MA... Read More

AUSTIN, Texas / Feb 23, 2023 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that Ruth E. Williams-Brinkley has been appointed to the Company’s board of directors. Williams-Brinkley has three decades of healthcare industry experience. She currently serves as president of Kaiser Permanente Health Plan of the Mid-Atlantic States (KPMAS), where she oversees the company’s... Read More

AUSTIN, Texas / Feb 21, 2023 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will release results for its fourth quarter and year ended December 31, 2022, after the market close on Feb. 28, 2023. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET). Earnings Conference Call Information: Event: Natera’s Fourth Quarter... Read More

AUSTIN, Texas / Feb 02, 2023 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the publication of a new paper in Pediatric Nephrology , which highlights the clinical utility of Renasight™ in aiding the diagnosis and management of kidney disease. The publication can be found here . This paper reviews the case of a 16-year-old patient with sickle cell disease (SCD) and... Read More

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced that new data on its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, will be presented at the American Society of Clinical Oncology's 2023 Gastrointestinal Cancers Symposium (ASCO GI), taking place January 19 – 21, 2023 in San Francisco, California. The presentations will highlight findings on the... Read More

New predictive data evaluates patient outcomes up to 24.8 months post-surgery, confirms findings presented at ASCO GI 2022 Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the publication of a new study in Nature Medicine , which demonstrates the ability of the Signatera TM molecular residual disease (MRD) test to identify patients with stage II-IV colorectal cancer (CRC) who are at an... Read More

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will webcast a live presentation at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 10, 2023 at 9:45 a.m. PT (12:45 p.m. ET). Members of Natera management will deliver a presentation and host a Q&A with the investment community at the conference. Interested parties may access the live webcast of the presentation... Read More

Natera, Inc. ( NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, announced its support for a recent guideline update by the International Society for Heart and Lung Transplantation (ISHLT), which includes the use of donor-derived cfDNA (dd-cfDNA) testing for surveillance of heart transplant recipients. The updated ISHLT guidelines, which were last revised in 2010, were published today in the Journal of Heart... Read More

Across all subtypes, in a real-world cohort of >200 patients and >900 plasma samples, the presence of ctDNA at any time was strongly associated with disease recurrence and poor prognosis AUSTIN, Texas , Dec. 9, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the publication of a new study in JCO Precision Oncology highlighting the clinical utility of its... Read More

AUSTIN, Texas , Dec. 7, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, plans to present new clinical data on its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, and its hereditary cancer test, Empower, at the 2022 San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas . Natera will present two posters from the LEADER and I-SPY 2... Read More

Study aligns with Natera's longstanding commitment to generate robust, real-world clinical evidence and highlights unique capabilities of Panorama SNP-based NIPT AUSTIN, Texas , Dec. 6, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the publication in Prenatal Diagnosis of a clinical experience study in twin pregnancies featuring its Panorama single nucleotide... Read More

AUSTIN, Texas , Nov. 23, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that Steve Chapman , chief executive officer, and Mike Brophy , chief financial officer, will be presenting at the Piper Sandler 34th Annual Healthcare Conference located at the Lotte New York Palace on Wednesday, November 30 at 12:00 p.m. PT ( 3:00 p.m. ET ). Interested parties may access the... Read More